中国·腾博-www.tengbo9885.com|官网首发

中文
中文
为了病患而驱动的创新
Patient-first cell therapy innovation

2022
  • 0
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. 
Cancer Cell 40, 674-693, June 13, 2022    doi:https://doi.org/10.1016/j.ccell.2022.04.018

Haixia Long, Qingzhu Jia, Liuyang Wang, Wenfeng Fang, Zhongyu Wang, Tao Jiang, Fei Zhou, Zheng Jin, Jiani Huang, Li Zhou, Chunyan Hu, Xinxin Wang, Jin Zhang, Yujie Ba, Yujie Gong, Xianghua Zeng, Dong Zeng, Xingxing Su, Peter B. Alexander, Li Wang, Limei Wang, Yisong Y. Wan, Xiao-Fan Wang, Li Zhang, Qi-Jing Li, Bo Zhu ( 2022)   

Breaking boundaries: current progress of anticancer NK cell-based drug development
Drug Discovery Today, PII: S1359-6446(22)00429-9 doi: https://doi.org/10.1016/j.drudis.2022.103436
Reference: DRUDIS 103436
Shuhang Wang, Kun Chen, Yale Jiang, Guo Zhao, Caie Wang, Hong Fang, Qiyu Tang, Chao Sun, Liang Zhang, Haiyang Wu, Li-Feng Zhang, Ning Li 

 
  • 上一篇:--
  • 下一篇:2021
06.14
2022
来源:
关键词:
相关阅读
关于腾博tengbo9885官网
研究与发展
产品及临床
新闻与媒体
招贤纳士

Copyright © 2019 腾博tengbo9885官网

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer
XML 地图